SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,281,409 | -39.9% | 3,600,648 | -13.3% | 0.00% | -40.0% |
| Q2 2023 | $86,944,497 | +6.5% | 4,154,061 | +7.4% | 0.01% | 0.0% |
| Q1 2023 | $81,654,538 | -56.0% | 3,866,230 | -47.0% | 0.01% | 0.0% |
| Q4 2022 | $185,706,766 | +195.3% | 7,296,926 | +178.8% | 0.01% | +25.0% |
| Q3 2022 | $62,897,000 | +34.2% | 2,617,437 | +7.5% | 0.00% | +33.3% |
| Q2 2022 | $46,859,000 | +13.3% | 2,435,517 | +2.3% | 0.00% | +50.0% |
| Q1 2022 | $41,370,000 | -23.8% | 2,380,337 | -4.0% | 0.00% | -33.3% |
| Q4 2021 | $54,292,000 | +35.1% | 2,480,204 | +17.9% | 0.00% | +50.0% |
| Q3 2021 | $40,197,000 | -26.2% | 2,103,447 | -33.7% | 0.00% | -33.3% |
| Q2 2021 | $54,436,000 | -8.3% | 3,170,432 | +19.5% | 0.00% | 0.0% |
| Q1 2021 | $59,332,000 | +57.0% | 2,653,471 | +56.1% | 0.00% | +50.0% |
| Q4 2020 | $37,802,000 | +128.9% | 1,699,720 | +51.9% | 0.00% | +100.0% |
| Q3 2020 | $16,512,000 | +135.5% | 1,118,720 | +136.5% | 0.00% | 0.0% |
| Q2 2020 | $7,012,000 | +45.3% | 473,120 | +7.6% | 0.00% | – |
| Q1 2020 | $4,826,000 | +24.8% | 439,902 | -0.1% | 0.00% | – |
| Q4 2019 | $3,868,000 | +24.6% | 440,535 | +6.0% | 0.00% | – |
| Q3 2019 | $3,104,000 | +2.7% | 415,564 | +28.0% | 0.00% | – |
| Q2 2019 | $3,022,000 | +137.0% | 324,546 | +33.6% | 0.00% | – |
| Q1 2019 | $1,275,000 | +31.0% | 242,918 | +11.1% | 0.00% | – |
| Q4 2018 | $973,000 | -38.5% | 218,652 | +11.6% | 0.00% | – |
| Q3 2018 | $1,583,000 | +46.4% | 195,858 | +27.2% | 0.00% | – |
| Q2 2018 | $1,081,000 | -41.6% | 154,007 | +18.5% | 0.00% | – |
| Q1 2018 | $1,851,000 | +81.6% | 129,941 | +11.7% | 0.00% | – |
| Q4 2017 | $1,019,000 | +2.8% | 116,290 | +37.6% | 0.00% | – |
| Q3 2017 | $991,000 | -12.8% | 84,534 | +3.9% | 0.00% | – |
| Q2 2017 | $1,137,000 | +35.2% | 81,327 | +32.8% | 0.00% | – |
| Q1 2017 | $841,000 | +99.3% | 61,221 | +3.9% | 0.00% | – |
| Q4 2016 | $422,000 | -49.8% | 58,921 | +6.5% | 0.00% | – |
| Q3 2016 | $840,000 | +87.5% | 55,322 | +21.5% | 0.00% | – |
| Q2 2016 | $448,000 | – | 45,546 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
| Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
| Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
| Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
| Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
| Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
| DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
| ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
| BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |